Therapeutics News and Research

RSS

Approaches designed to motivate drug development for children needed

Recent legislative and regulatory actions make great strides toward establishing much needed incentives for pharmaceutical companies and others to develop and test more medications for pediatric rare diseases, including pediatric cancers, according to commentary by experts from Children's National Medical Center. The commentary appears in the January 19 issue of Science Translational Medicine.

21 Jan 2011

Math may help assess how rapidly stem cells and cancer-causing cousins increase numbers

The difficult task of sorting and counting prized stem cells and their cancer-causing cousins has long frustrated scientists looking for new ways to help people who have progressive diseases.

21 Jan 2011

EMA CHMP issues negative opinion against Biogen Idec's FAMPYRA for multiple sclerosis

Biogen Idec announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion recommending against approval of FAMPYRA to improve walking ability in adult patients with multiple sclerosis (MS) in the European Union. Biogen Idec intends to appeal this opinion and request a re-examination of the decision by the CHMP.

21 Jan 2011

Precision highlights role of ChemoFx test, multi-gene predictors for breast cancer

In a new study in which Precision Therapeutics' Multi-Gene Predictors were independently validated by investigators at US Oncology and MD Anderson, Precision highlights the potential role of the ChemoFx® in vitro chemosensitivity test and multi-gene predictors in determining a patient's likelihood of response to multi-drug chemotherapy regimens in breast cancer.

21 Jan 2011

Pervasis to present PVS-10200 interim data from Phase 1/2 PAD clinical study at IC3D

Pervasis Therapeutics, Inc. today announced it will present interim data from the company's Phase 1/2 clinical study of PVS-10200, an investigational cell-based therapy under development to prevent restenosis in patients with peripheral arterial disease (PAD) who undergo an angioplasty and stent procedure in the superficial femoral artery.

21 Jan 2011

Teva invests $3.95M in Rexahn for development of anti-cancer compound RX-3117

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, announced that Teva Pharmaceutical Industries Limited (Teva) purchased 2,334,515 shares of Rexahn's common stock in a private offering for $3.95 million, or $1.692 per share.

21 Jan 2011

NeoStem completes merger with Progenitor Cell Therapy

NeoStem, Inc. and Progenitor Cell Therapy LLC announced today the closing of their previously announced merger transaction.

21 Jan 2011

OriGene releases 1,500 mouse monoclonal antibodies

OriGene Technologies, Inc. has recently achieved a significant milestone in its quest for developing an assay for every human protein through the release of 1,500 mouse monoclonal antibodies under the TrueMAB brand. Each TrueMAB antibody is specifically developed with full-length human proteins produced in HEK293T cells and validated for critical research and diagnostic needs requiring improved antibody sensitivity and specificity.

21 Jan 2011

ACT Biotech releases telatinib Phase 2 trial data for metastatic stomach cancer

ACT Biotech, a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, today released data on additional analysis of the Phase 2 clinical trial of telatinib in patients with metastatic stomach cancer that further supports the highly-potent nature of the antiangiogenic agent.

21 Jan 2011

Scientists decipher genetic code for a pancreatic cancer type

Scientists at Johns Hopkins have deciphered the genetic code for a type of pancreatic cancer, called neuroendocrine or islet cell tumors. The work, described online in the Jan. 20 issue of Science Express, shows that patients whose tumors have certain coding "mistakes" live twice as long as those without them.

21 Jan 2011

Cognition Therapeutics closes $2.5 million Series A1 financing

Cognition Therapeutics Inc., a drug discovery company developing novel, small molecule disease-modifying treatments for Alzheimer's, has closed on a $2.5 million Series A1 financing it will use to bring one or more of its compounds to Investigational New Drug (IND) candidate status. The round was led by Golden Seeds, one of the nation's largest angel investing groups, and was syndicated with Tech Coast Angels.

20 Jan 2011

Chelsea reports top-line data from Phase III NORTHERA extension study in NOH

Chelsea Therapeutics International, Ltd. reported new 12-month data from Study 303, a safety extension study from its Phase III NORTHERA™ (droxidopa) registration program in symptomatic neurogenic orthostatic hypotension (NOH). Preliminary, top-line results demonstrate Northera provides clinically meaningful and durable symptomatic improvements in patients with NOH throughout a one-year observation period.

20 Jan 2011

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

Allos Therapeutics, Inc. today announced that the Journal of Clinical Oncology has published data from the Company's pivotal Phase 2 PROPEL study demonstrating clinical activity of FOLOTYN® (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

20 Jan 2011

Pervasis pursues matrix-embedded endothelial cell-based therapy to target and regulate cell stroma

Pervasis Therapeutics, Inc. today announced that the company is pursuing a matrix-embedded endothelial cell-based therapy (PVS-30200) to target and regulate cell stroma (the tumor environment or "ecosystem" that is comprised of various supporting cell types distinct from cancer cells) in order to prevent key processes that play a role in advancing solid tumor growth and metastasis.

20 Jan 2011

Koronis' KP-1461 drug causes extra mutations to occur in HIV genome in HIV-infected patients

Recently published Phase 2a clinical trial results show that the frequency of specific, drug-induced mutations in the HIV genome can be significantly increased by administering KP-1461, a drug being developed by Koronis Pharmaceuticals based on its novel Viral Decay Acceleration (VDA) drug mechanism.

20 Jan 2011

Precision Therapeutics to present pancreatic cancer data at 2011 ASCO GI Symposium

Precision Therapeutics, will present pancreatic cancer data based on Precision's ChemoFx in-vitro chemosensitivity test at the 2011 American Society of Clinical Oncology GI Symposium, January 20-22 in San Francisco, California.

20 Jan 2011

DARPA grants $5.6 million to Dana-Farber to develop viable countermeasures against unknown pathogen

Researchers at Dana-Farber Cancer Institute have received a $5.6 million grant from the Defense Advanced Research Projects Agency and the Army Research Office to develop transient immunity against known, unknown, naturally occurring, or engineered disease-causing pathogens.

20 Jan 2011

Endothelial cells may play a role in controlling cancer behavior: New study

MIT scientists have discovered that cells lining the blood vessels secrete molecules that suppress tumor growth and keep cancer cells from invading other tissues, a finding that could lead to a new way to treat cancer.

20 Jan 2011

Autism Speaks Autism Treatment Network adds 17 sites in Canada and the U.S

Autism Speaks and Autism Speaks Canada who together form North America's largest autism science and advocacy organization, is pleased to announce the expansion of its Autism Treatment Network to include 17 leading children's hospitals and academic medical centers in the Canada and the U.S.

20 Jan 2011

OXiGENE reaches agreement with warrant holders for warrant exchange

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, has entered into separate Warrant Exchange Agreements with each of the holders of outstanding warrants originally issued in March 2010 to eliminate all of such warrants having "ratchet" price-based anti-dilution protection features in exchange for shares of Company common stock and a lower number of warrants having no price based anti-dilution protections.

19 Jan 2011

Therapeutics News and Research

Approaches designed to motivate drug development for children needed

Math may help assess how rapidly stem cells and cancer-causing cousins increase numbers

EMA CHMP issues negative opinion against Biogen Idec's FAMPYRA for multiple sclerosis

Precision highlights role of ChemoFx test, multi-gene predictors for breast cancer

Pervasis to present PVS-10200 interim data from Phase 1/2 PAD clinical study at IC3D

Teva invests $3.95M in Rexahn for development of anti-cancer compound RX-3117

NeoStem completes merger with Progenitor Cell Therapy

OriGene releases 1,500 mouse monoclonal antibodies

ACT Biotech releases telatinib Phase 2 trial data for metastatic stomach cancer

Scientists decipher genetic code for a pancreatic cancer type

Cognition Therapeutics closes $2.5 million Series A1 financing

Chelsea reports top-line data from Phase III NORTHERA extension study in NOH

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

Pervasis pursues matrix-embedded endothelial cell-based therapy to target and regulate cell stroma

Koronis' KP-1461 drug causes extra mutations to occur in HIV genome in HIV-infected patients

Precision Therapeutics to present pancreatic cancer data at 2011 ASCO GI Symposium

DARPA grants $5.6 million to Dana-Farber to develop viable countermeasures against unknown pathogen

Endothelial cells may play a role in controlling cancer behavior: New study

Autism Speaks Autism Treatment Network adds 17 sites in Canada and the U.S

OXiGENE reaches agreement with warrant holders for warrant exchange

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News